Showing results (241-250 of 256) with videos related to

Sort By:
Pageof 26
World Neurosurgery|June 2, 2022
Robust Prediction of Non-home Discharge After Thoracolumbar Spine Surgery With Ensemble Machine Learning and Validation on a Nationwide CohortAly A Valliani, Nora C Kim, Michael L Martini, et al.
Clinical Spine Surgery|January 29, 2024
Reliable Prediction of Discharge Disposition Following Cervical Spine Surgery With Ensemble Machine Learning and Validation on a National CohortRui Feng, Aly A Valliani, Michael L Martini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 27, 2018
Prophylactic irradiation to the contralateral breast for BRCA mutation carriers with early-stage breast cancerE Evron, A M Ben-David, H Goldberg, et al.
World Neurosurgery|December 20, 2023
Clinical Considerations and Outcomes for Spine Surgery Patients with a History of Transplant: A Systematic Scoping ReviewRoshini Kalagara, Zerubabbel K Asfaw, Matthew Carr, et al.
The American Journal of Cardiology|October 2, 2021
Pericarditis Recurrence After Initial Uncomplicated Clinical CourseMarco Giuseppe Del Buono, Alessandra Vecchié, Juan Ignacio Damonte, et al.
Chest|July 28, 2020
Clinical Presentation and Outcomes of Acute Pericarditis in a Large Urban Hospital in the United States of AmericaAlessandra Vecchié, Juan G Chiabrando, Megan S Dell, et al.
World Neurosurgery|July 24, 2020
Afternoon Surgical Start Time Is Associated with Higher Cost and Longer Length of Stay in Posterior Lumbar FusionSean N Neifert, Michael L Martini, Jonathan S Gal, et al.
Spine Deformity|May 2, 2020
Adult spinal deformity surgery: the effect of surgical start time on patient outcomes and cost of careWilliam H Shuman, Sean N Neifert, Jonathan S Gal, et al.
Spine Deformity|May 20, 2020
Correction to: Adult spinal deformity surgery: the effect of surgical start time on patient outcomes and cost of careWilliam H Shuman, Sean N Neifert, Jonathan S Gal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 10, 2016
Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancerE Vrdoljak, N Marschner, C Zielinski, et al.
Pageof 26